BillionToOne, Inc. (BLLN) stock surged +4.22%, trading at $86.12 on NASDAQ, up from the previous close of $82.63. The stock opened at $81.89, fluctuating between $80.41 and $89.18 in the recent session.
| Filing Date | Accepted Date | |
|---|---|---|
| Filing Date | Accepted Date | |
|---|---|---|
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| May 18, 2026 | 81.89 | 89.18 | 80.41 | 86.12 | 600.46K |
| May 15, 2026 | 87.19 | 90.00 | 81.97 | 82.63 | 1.11M |
| May 14, 2026 | 89.31 | 92.49 | 87.01 | 87.94 | 501.28K |
| May 13, 2026 | 93.00 | 95.21 | 90.00 | 90.59 | 613.47K |
| May 12, 2026 | 98.26 | 102.90 | 93.45 | 94.23 | 1.29M |
| May 11, 2026 | 92.71 | 107.00 | 91.61 | 105.94 | 1.1M |
| May 08, 2026 | 90.00 | 94.46 | 85.10 | 92.96 | 1.3M |
| May 07, 2026 | 81.60 | 93.00 | 77.10 | 92.90 | 1.29M |
| May 06, 2026 | 77.00 | 83.05 | 73.57 | 81.40 | 708.39K |
| May 05, 2026 | 72.01 | 80.48 | 72.01 | 79.90 | 1.52M |
| May 04, 2026 | 77.49 | 78.99 | 70.81 | 72.12 | 697.37K |
| Apr 30, 2026 | 77.80 | 78.00 | 72.99 | 75.05 | 445.61K |
| Apr 29, 2026 | 78.23 | 79.16 | 71.00 | 73.71 | 289.29K |
| Apr 28, 2026 | 82.09 | 82.25 | 75.96 | 78.23 | 369.65K |
| Apr 27, 2026 | 84.98 | 86.60 | 81.65 | 81.76 | 232.49K |
| Apr 23, 2026 | 87.13 | 88.12 | 82.03 | 83.93 | 345.41K |
| Apr 22, 2026 | 91.02 | 91.02 | 86.01 | 86.84 | 210.73K |
| Apr 21, 2026 | 88.00 | 94.00 | 85.55 | 89.00 | 617.71K |
| Apr 20, 2026 | 80.57 | 87.11 | 79.08 | 86.97 | 793.78K |
| Apr 17, 2026 | 80.99 | 84.47 | 78.90 | 79.43 | 493.86K |
BillionToOne, Inc., a precision diagnostics company, quantifies biology to create molecular diagnostics. The company provides molecular counting platform, which is designed to detect and measure DNA molecules at the single-count level to help enhance disease detection. It offers UNITY Complete, a non-invasive prenatal screen that assesses fetal risk for aneuploidies, recessive conditions, and fetal antigens from a maternal blood draw; Northstar Select, a liquid biopsy test that provides a list of mutations that are present in the tumor and types of mutations detected that include deletions, insertions, and point mutations; and Northstar Response, a test that provides longitudinal determination of cancer burden through methylation assessment. The company was incorporated in 2016 and is headquartered in Menlo Park, California.
| Employees | 620 |
| Beta | 6.3 |
| Sales or Revenue | N/A |
| 5Y Sales Change% | N/A |
| Fiscal Year Ends | N/A |
| Sector | Healthcare |
| Industry | Medical - Diagnostics & Research |
© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep